The COVID-19 pandemic’s influence on healthcare systems led to mixed outcomes for patients with cirrhosis, showing stable infection rates but a rise in multi-drug resistant organism (MDRO) infections.
The COVID-19 pandemic’s influence on healthcare systems led to mixed outcomes for patients with cirrhosis, showing stable infection rates but a rise in multi-drug resistant organism (MDRO) infections.